Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.

× No keyword cloud information.

8 in total

Review 1. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Authors: Rashmi R Shah
Journal: Drug Saf Date: 2017-03 Impact factor: 5.606

Review 2. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

Authors: Jeryl Villadolid; Jennifer L Ersek; Mei Ka Fong; Lindsey Sirianno; Ellen S Story
Journal: Transl Lung Cancer Res Date: 2015-10

3. Antidiabetic Effects of the Senolytic Agent Dasatinib.

Authors: Omid Salaami; Chia-Ling Kuo; Matthew T Drake; George A Kuchel; James L Kirkland; Robert J Pignolo
Journal: Mayo Clin Proc Date: 2021-11-09 Impact factor: 7.616

4. Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus.

Authors: Ji Min Kim; Sorim Choung; Kyong Hye Joung; Ju Hee Lee; Hyun Jin Kim; Bon Jeong Ku
Journal: Diabetes Metab J Date: 2018-05-02 Impact factor: 5.376

5. Statistical Bioinformatics to Uncover the Underlying Biological Mechanisms That Linked Smoking with Type 2 Diabetes Patients Using Transcritpomic and GWAS Analysis.

Authors: Abu Sayeed Md Ripon Rouf; Md Al Amin; Md Khairul Islam; Farzana Haque; Kazi Rejvee Ahmed; Md Ataur Rahman; Md Zahidul Islam; Bonglee Kim
Journal: Molecules Date: 2022-07-08 Impact factor: 4.927

Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.

Review 1. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Review 2. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

3. Antidiabetic Effects of the Senolytic Agent Dasatinib.

4. Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus.

5. Statistical Bioinformatics to Uncover the Underlying Biological Mechanisms That Linked Smoking with Type 2 Diabetes Patients Using Transcritpomic and GWAS Analysis.

Review 6. Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.

Review 7. Updates on Immune Therapies in Type 1 Diabetes.

Review 8. Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects.